<DOC>
	<DOC>NCT01119950</DOC>
	<brief_summary>This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.</brief_summary>
	<brief_title>Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male and female patients age 40 years or more Diagnosis of Chronic Obstructive Lung Disease (COPD) (moderate to severe as classified by the Global Initiative for COPD (GOLD) Guidelines, 2008 Smoking history of at least 10 packyears Postbronchodilator Forced Expiratory Volume in 1 second (FEV1) &lt;80% and â‰¥30% of the predicted normal value Postbronchodilator FEV1/Forced Vital Capacity (FVC) &lt;0.7 Symptomatic patients, according to daily electronic diary data between visit 2 (Day 8) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to visit 3 Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to the first visit Patients who have had a respiratory tract infection within 4 weeks prior to the first visit Patients with concomitant pulmonary disease Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Patients with a history of asthma or a blood eosinophil count &gt;600/mm3 or onset of symptoms prior to 40 years Patients with eczema, known high IgE levels or a known positive skin prick test Patients participating in the active phase of a pulmonary rehabilitation programme Patients contraindicated for the treatment with anticholinergics, long and shortacting beta2 agonists or sympathomimetic amines Patients with a history of alpha1 antitrypsin deficiency Patients on long term oxygen therapy (&gt;15hr per day) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>COPD</keyword>
</DOC>